News for Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences, a strategic partner with Gilead Sciences, gains FDA orphan drug designation for its promising pancreatic cancer treatment. Wall Street an

Arcus Biosciences, identified by its ticker RCUS, has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting orphan drug sta

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

Arcus Biosciences (RCUS) grants stock options and restricted stock units to six new employees under its 2020 Inducement Plan. A total of 54,800 shar

Arcus Biosciences (RCUS) grants new employment inducement awards as part of their 2020 Inducement Plan. A total of 8,400 stock options and 4,200 restric

Arcus Biosciences (RCUS) recently showcased initial results for their investigational combination therapy, casdatifan plus cabozantinib, at the 2025 American So

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

Arcus Biosciences (RCUS) grants new employees options and stock units under its 2020 Inducement Plan. A total of 13,400 stock options and 13,400 restric

On May 9, 2025, Morgan Stanley, led by analyst Terence Flynn, updated its assessment of Arcus Biosciences (RCUS), maintaining its "Overweight" rating. Despite r

Wells Fargo analyst Eva Fortea Verdejo has revised the firm's target price for Arcus Biosciences (RCUS), lowering it from $29 to $26 while maintaining an Overwe

Cash Position: $1 billion as of the end of the first quarter 2025, compared to $992 million at the end of 2024.Equity Financing: $150 million completed in Febr

May 06, 2025 / 08:30PM GMTOperator Hello, everyone. And welcome to Arcus Biosciences first quarter 2025 earnings and financial results call. My name is Lydia, a

Arcus Biosciences, Inc. (NYSE:RCUS) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ETCompany ParticipantsPia Eaves - VP, IRTerry Rosen - CEORichard...

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -11.76% and 14.24%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapie

Arcus Biosciences (RCUS) Q1 results: GAAP EPS of -$1.14 & $28M revenue miss estimates.

U.S. stock futures were lower this morning, with the Dow futures falling over 200 points on Tuesday. Shares of Ichor Holdings, Ltd. ICHR fell sharply in today'...